BCDA

BioCardia is a clinical-stage cell-therapy developer that has stopped generating revenue entirely — FY2025 revenue was $0.00, down from $58K in FY2024 and $1.35M in FY2022 — while burning $7.44M of operating cash a year. Against that burn it held just $2.50M of cash and equivalents at year-end. That is materially less than one year of runway, and the balance sheet is skeletal: $3.41M total assets, $2.52M liabilities, and only $895K of stockholders' equity against a $168M accumulated deficit. The MD&A confirms the model — 'we have funded our operations primarily through the sales of equity and convertible debt securities' — which is why shares outstanding jumped 133.8% in a single year to 10.9M. A holder here is on a dilution treadmill: the company must keep issuing stock to survive, and the -919% ROE is an artifact of a near-zero equity base being consumed by losses.

The fundamental case for owning it would rest on the CardiAMP pipeline, and the filing undercuts that. Management discloses plainly that the pivotal CardiAMP Heart Failure Trial 'did not meet the primary endpoint.' The salvage narrative — favorable results in a post-hoc subgroup of elevated-NTproBNP patients (a 47% relative risk reduction in heart-death equivalents in ~50% of enrollees) — is a retrospective subgroup finding, not a passed trial, and the allogeneic MSC and ARDS programs remain earlier-stage (the ARDS IND is approved but 'we have not yet advanced this program in the clinic'). None of this is near commercialization, and there is no partner revenue or approved product cash flow to bridge the gap.